| Identification | Back Directory | [Name]
AB 1010 Mesylate | [CAS]
1048007-93-7 | [Synonyms]
AB1010 Mesylate
AB-1010 Mesylate
Masivet Mesylate
AB 1010 Mesylate
Masitinib (Mesylate)
Masitinib mesylate
(AB1010 mesylate
AB1010 MESYLATE;AB-1010 MESYLATE;AB 1010 MESYLATE
AB1010 MESYLATE; MASIVET MESYLATE; AB-1010 MESYLATE; AB 1010 MESYLATE
N-(4-methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide methanesulfonate
Benzamide,4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-,methanesulfonate
methanesulfonicacid,4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide | [Molecular Formula]
C29H34N6O4S2 | [MOL File]
1048007-93-7.mol | [Molecular Weight]
594.748 |
| Hazard Information | Back Directory | [Uses]
Masitinib is a novel tyrosine kinases inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, resectively. | [Uses]
Masitinib Mesylate can be used to treat sickle cell disease. | [in vivo]
Masitinib inhibits tumour growth and increases the median survival time in Δ27-expressing Ba/F3 tumor models at 30 mg/kg, without cardiotoxicity or genotoxicity[1].
Masitinib (12.5 mg/kg/d, p.o.) increases overall TTP (time-to-tumor progression) compared with placebo in dogs[3]. | [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
|